CoChat

101. Toxicology and Biodistribution Studies of a Recombinant Adeno-Associated Virus 2 (rAAV2) Alpha-1 Antitrypsin (AAT) Vector

Open access
· 2004 · Molecular Therapy
Cited by 12

The DOI matches its Crossref record.

Abstract

A series of safety and biodistribution studies were undertaken to support the development of a muscle-based gene therapy system for AAT deficiency. AAT is the primary circulating serum proteinase inhibitor, and its deficiency can result in emphysema. The test article that was used in this toxicology study was rAAV serotype 2 with the CMV/Beta Actin promoter driving expression of the human AAT gene. There were 4 dosing arms in the primary toxicology study (PTS) with sacrifice time points being at 21 days and 90 days post vector administration. In the biodistribution study (BDS), there were 5 dosing arms with duplicate doses given intramuscularly and intravenously. The sacrifice time point for this study was at 60 days post vector administration. The PTS was performed in 48-C57/Bl6 mice (24M/24F) with the primary safety endpoint being the histopathologic examination of organs collected at necropsy. CBC and serum chemistry analyses were also performed. Gene transfer efficiency was evaluated from gDNA isolated from organs and whole blood by real-time PCR. The BDS was performed in 36-C57/Bl6 mice (18M/18F) to determine the potential for vector dissemination following test article administration IV and IM. In the PTS, no abnormalities were noted in the CBC and serum chemistry data among test article and control article study arms. Histopathology results were essentially normal with no vector related findings. Real Time PCR indicated that vector DNA was present in the peripheral blood 24 hours post administration, but decreased to near baseline levels at the time of sacrifice. Vector DNA was not detectable in gonad tissue. Real Time PCR results in the BDS also indicated vector DNA present in peripheral blood at 24 hours post vector administration. At sacrifice, IV injected mice vector levels were higher than IM injected mice. Vector DNA was found in skeletal muscle, lung, heart, liver, diaphragm, kidney and pancreas at the time of necropsy via IM administration at dose dependent levels. No vector DNA was detected in the skeletal muscle following IV administration, but substantial amounts were found in other organs. Gonads were negative for vector DNA with both IM and IV administration indicating that the risk of germline transmission with our gene therapy vector would be relatively low.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2004.06.036

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 12

Metadata

Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2004-05
Volume
9
Pages
S40
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2093023120
Cited by
12
References
0
FWCI
0.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 101. Toxicology and Biodistribution Studies of a Recombinant Adeno-Associated Virus 2 (rAAV2) Alpha-1 Antitrypsin (AAT) Vector. https://app.cochat.ai/papers/10.1016/j.ymthe.2004.06.036
The paper
101. Toxicology and Biodistribution Studies of a Recombinant Adeno-Associated Virus 2 (rAAV2) Alpha-1 Antitrypsin (AAT) Vector. (2004). Molecular Therapy. https://doi.org/10.1016/j.ymthe.2004.06.036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.